Neuroscience

Global informatics provider IDBS announced in early November that BioFocus DPI, the service division of Galapagos, will use IDBS BioBook to handle all of its ADME data management needs.

In a deal that locks up its rights to a pair of alpha-7 agonist drug candidates targeting Alzheimer’s disease and schizophrenia, Roche announced in late November that it signed a definitive merger agreement to acquire all the shares of Memory Pharmaceuticals Inc. for 61 cents per share—a premium more than 300 percent over the previous day closing price for Memory.

Varian and GE Healthcare join forces to develop a new 7T MR preclinical imaging system

Valeant gets $800 million for its neuronal potassium channel opener epilepsy candidate

University of Maryland researchers see commercial opportunity for novel data mining software

Scientists at the University of Otago have shown for the first time the key ovulation-triggering role of kisspeptin, a small protein molecule in the brain, a discovery that could lead to new treatments for infertility.

Seven years ago, Genentech shares were trading for roughly $22 per share and Roche had been the majority owner of the company for a bit more than 10 years. In 2001, with agreements in place that would provide Roche with first choice to pick Genentech’s ripest fruit, I’m sure 2015 seemed forever in the future. But not anymore.

Australian scientists are reporting marked improvement in Alzheimer’s transgenic mice following treatment with the ionophore PBT2, a finding the scientists believe could lead to the development of the first disease-modifying drug for Alzheimer’s Disease.

Linguamatics Ltd., a provider of enterprise text mining for life science researchers, announced in June that it has joined the Microsoft BioIT Alliance, an association of life science organizations and informatics companies whose focus is to enhance collaboration and accelerate the pace of drug discovery and development.

LabVantage, InforSense integrate data management and analytics platforms

Researchers from the National Institute of Environmental Health Sciences (NIEHS) and the University of Minnesota have gained new insight into one of the most puzzling aspects of epilepsy treatment: why some epileptics fail to respond to anti-epileptic medications.

Agilent, Accelrys take partnership to the next level